from mother cells to daughter cells. Its SET and RING finger-associated (SRA) domain recognizes hemi-methylated DNA that appears in newly synthesized daughter DNA strands during duplication of DNA strands through the S phase (Arita et al., 2008; Avvakumov et al., 2008; Hashimoto et al., 2008) . UHRF1 recruits DNA methyltransferase 1 (DNMT1) to the site with proliferating cell nuclear antigen (PCNA) and methylates the newly synthesized strands (Achour et al., 2008; Sharif et al., 2007) . UHRF1 also recognizes tri/di-methylated H3K9, and recruits the H3K9 methyltransferase G9a, the histone deacetylase 1 (HDAC1), and the histone acetylase Tip60 (Achour et al., 2009; Hashimoto et al., 2009; Karagianni et al., 2008; Kim et al., 2009; Unoki et al., 2004) , indicating that UHRF1 links DNA methylation and histone modification status (Fig. 1) . Fig. 1 . Proposed mechanism of heterochromatin formation through UHRF1 at DNA replication fork or DNA repair site. 1) UHRF1 binds to PCNA and the SRA domain of UHRF1 recognizes hemi-methylated CpG on newly synthesized DNA. Then histones are reassembled. 2) UHRF1 recruits DNMT1 to methylate both DNA strands to transfer methylation status. UHRF1 also recruits G9a to methylate histone H3K9. Methylated histone H3K9 interacts with the Tudor-PHD domain of UHRF1. 3) UHRF1 recruits HDAC1 to the site and deacetylates histones. Then, histones become charged positively and bind to negatively charged DNA tightly, causing heterochromatin formation. This figure is cited from our article (Unoki et al., 2009a) . UHRF1 promotes G1/S transition (Arima et al., 2004; Jeanblanc et al., 2005) and is a direct target of E2F transcription factor 1 (E2F1) Mousli et al., 2003; Unoki et al., 2004) . The tumour suppressor p53, which is deficient in 50% of all human cancers (Hussain & Harris, 2000) , indirectly down-regulates UHRF1 through up-regulation of p21/WAF1 and subsequent deactivation of E2F1 (Arima et al., 2004) (Fig. 2) . 
UHRF1 is overexpressed in bladder cancer
Considering these features of UHRF1, we thought that UHRF1 could be also important for bladder carcinogenesis, and examined expression of UHRF1 in bladder cancer specimens obtained from 124 UK cases (Table 1 ) and 36 Japanese cases (Unoki et al., 2009b) . As a result, we found that UHRF1 was significantly overexpressed in bladder cancers at the mRNA and protein level (Fig. 5 and Fig. 6) . Because overexpression of UHRF1 in the cancer was detected both in UK cases and also in Japanese cases, the overexpression of UHRF1 could be common worldwide. Recently, another group showed that UHRF1 is also overexpressed in superficial, non-muscleinvasive bladder cancer of Chinese cases (Yang et al., 2011) . Their result supports our observation. We also examined correlation between expression of UHRF1, p53, and p21/WAF1, and observed accumulation of stabilized p53 protein, which is probably mutated, in cancer tissues at grade II-III. However, we did not observe any accumulation of p53 in cancer tissues at grade I, although overexpression of UHRF1 was observed in this grade ( Fig. 7 ). There was no relationship between expression levels of UHRF1 and p21 mRNA. Therefore, UHRF1 seems to be superior to p53 as a potential diagnostic marker of bladder cancer. This result is concordant with the fact that p53 is mutated only in 10-30 % of bladder cancer cases ( . Expression levels of UHRF1 mRNA in urinary system tumours and normal tissues detected by TaqMan qRT-PCR. Expression of UHRF1 in 12 different normal tissues, 21 normal kidneys, 6 oncocytomas, 71 kidney tumours, 21 normal bladders, and 124 bladder tumours, including 112 bladder located transitional cell carcinomas (TCCs) and 12 TCCs occurred in upper tract, were compared. Expression of UHRF1 differed among the seven groups (p<0.0001, Kruskal-Wallis' test). Expression of UHRF1 in the kidney cancers was higher than that in the normal kidneys and also in the oncocytomas significantly (p<0.0001, and p=0.0206, respectively, Mann-Whiteney's U-test), but expression levels of UHRF1 in the bladder cancers were much higher than those in the kidney cancers (p<0.0001, Mann-Whiteney's U-test). Among the bladder cancers, expression of UHRF1 was significantly high in upper tract TCCs (n=12) compared with the bladder-origin bladder tumours (n=112) (Mann-Whiteney's U-test; p=0.0042). 2-microgloblin was used for normalization. Asterisk indicates statistically significant p-values. This figure is cited from our article (Unoki et al., 2009b) . (Unoki et al., 2009b) .
We also examined expression of UHRF1 in kidney cancer, another urinary system tumour, together with the bladder cancer by immunohistochemistry. Although overexpression of UHRF1 is significant at mRNA level ( Fig. 5 ), expression of UHRF1 in kidney cancer was not detected at protein level ( Fig. 8A ). Therefore, immunohistochemical staining of UHRF1 in the cancer seems not to be useful. However, overexpression of UHRF1 at the mRNA level was associated with several characteristics of kidney cancer patients including 5-year survival rates, pathological staging and histological grade ( Fig. 8B-D) . Thus, detection of www.intechopen.com UHRF1 mRNA overexpression in surgical specimen might be useful as a prognosis tool in kidney cancer. 
Expression level of UHRF1 correlates with malignancy of bladder cancer
We examined correlations between UHRF1 expression in bladder cancer and various clinical features of the patients (Table 1) . Among these features, the expression of UHRF1 correlated with the T-category and the WHO histological grading significantly ( Fig. 9A and 9B) . Expression level of UHRF1 in superficial bladder cancers (T-category: Ta and T1) and invasive bladder cancers (T-category classification: T2, T3 and T4) was both significantly higher than that in normal bladders. This result is concordant with data from the another group (Yang et al., 2011) . In addition, expression of UHRF1 in invasive bladder cancers was higher than that in superficial cancers, when we compared the three groups, normal bladders, invasive bladder cancers (pTa, pT1), and superficial bladder cancers (pT2-4), by Kruskal-Wallis's test (Fig. 9A ). In addition, expression level of UHRF1 in cancers with grade-II and -III was up-regulated compared with that in normal bladders (Fig. 9B) . Therefore, up-regulation level of UHRF1 reflects progression level of bladder cancer. In our result, expression of UHRF1 was not associated with difference of gender, numbers of tumour, tumour size, growth pattern (papillary or solid), incidence of recurrence, survival status after five years from surgery, and smoking history (Fig. 10) , although the another group showed an association between UHRF1 expression levels and tumour recurrence in superficial bladder cancer of Chinese cases (Yang et al., 2011) . Therefore, UHRF1 could be a molecular marker for predicting the recurrence of superficial bladder cancers in some ethnic groups. Fig. 10 . Expression of UHRF1 detected by TaqMan qRT-PCR and many characteristics of patients were compared by Mann-Whiteney's U-test. A. Expression levels of UHRF1 in female patients (n=29) and male patients (n=75). Gender was not associated with expression levels of UHRF1 (p=0.2162). B. Expression levels of UHRF1 in patients with tumours four and less (n=53) and more than four (n=9) were not different (p=0.2896). C. Expression levels of UHRF1 in patients with ≤ 5cm tumours (n=38) and with >5 cm tumours (n=20) were not different (p=0.4567). D. Expression levels of UHRF1 in patients with papillary type tumours (n=32) and with solid or solid/papillary tumours (n=28) were not different (p=0.4567). E. Expression levels of UHRF1 in patients who did not have a recurrence (n=19) and have a recurrence (n=46) were not different (p=0.6239). F. Expression levels of UHRF1 in patients who survived 5 years after surgery (n=45) and died within 5 years (n=48) were not different (p=0.4151). G. Expression levels of UHRF1 in non-smoker patients (n=22) and smoker patients including 4 exsmokers (n=40) was not different (p=0.0750). 2-microgloblin was used for normalization.
Expression UHRF1 can be used for predicting recurrence risk after TURBT
Over 75% bladder cancer patients have one or more superficial bladder cancers, and two thirds of them will develop recurrent disease (Lutzeyer et al., 1982) , with 10-20% progressing to an invasive phenotype (Torti & Lum, 1984) . The outcome of patients with invasive tumours remains still poor, with distant metastasis occurring in over 50% within 2 years and an average 5-year survival of only 50% (Raghavan et al., 1990) . Currently, superficial bladder cancers are resected by a procedure called TURBT (TransUrethral Resection of Bladder Tumour), and patients are treated differently based on estimated recurrence risk after TURBT. Thus, diagnosis of bladder cancer at non-advanced stage and also precise estimation of the risk after the TURBT, are very important for prognosis of patients. Currently, the risk after the surgery is estimated by a scoring system and risk tables developed by European Organization for Research and Treatment of Cancer (EORTC). The EORTC scoring system was developed based on the six most significant clinical and pathological factors, which are tumour stage, tumour grade, numbers of tumour, tumour size, prior recurrence rate, and presence of carcinoma in situ (CIS). Bladder cancer patients with pTaG1 tumours (50% of all patients) are at very low risk, and those with CIS or with pT1G3 tumours are at the highest risk (15% of all patients). Intermediate risk patients are those with pTa/pT1 G1/G2 disease who develop multiple recurrent cancers (35% of all patients). Our TaqMan qRT-PCR result showed that high expression of UHRF1 was associated with high risk after TURBT (Fig. 11) , probably because reflecting the association between high expression of UHRF1 and stage, and/or grade ( Fig. 9A and 9B ). Based on these results, detection of UHRF1 in tissue samples after TURBT will be a prognostic marker of future recurrence and may help to determine the risk together with the current prognostic factors. Fig. 11 . Expression of UHRF1 correlated with the recurrence risk after TURBT. Significant high expression of UHRF1 in the high risk group after TURBT (n=23) was observed compared with that in the low risk group (n=7) by Mann-Whiteney's U-test (p=0.0350).
Asterisk indicates statistically significant p-values. 2-microgloblin was used for normalization. This figure is cited from our article (Unoki et al., 2009b) .
UHRF1 is a possible marker of bladder cancers and upper tract TCCs
Because UHRF1 was significantly overexpressed in bladder cancers and upper tract TCCs (Fig. 5) , UHRF1 might be a useful diagnostic marker especially for upper tract TCCs.
Upper tract TCCs are often very malignant when it is diagnosed, partially because it is relatively difficult to find at an early stage. If the cancer is found at an early stage, the prognosis of patients is improved. The development of a sensitive urine based detection marker is still being sought. Examination of voided urine or bladder barbotage for exfoliated cancer cells is useful for diagnosis of urothelial tumours anywhere in the urinary tract, from the calyx, through the ureters, into bladder and urethra. However, cytological interpretation can be problematic; low cellular yields, atypia, degenerative changes, urinary tract infections, stones and intravesical instillations hamper a correct diagnosis. Because the current two biomarker tests in clinical use, NMP-22 detection and BTA stat/BTA TRAK assay, can be hampered by existence of bleeding, inflammation, recent genitourinary tumours, and bladder stone (Dey, 2004) , these markers have not improved the traditional cytology-based bladder cancer diagnosis largely. Thus, cytology is still the mainstay for diagnosing bladder cancer. Because the expression of UHRF1 in peripheral blood mononuclear cells (PBMCs) was under detection limit of qRT-PCR (Fig.  12) , the presence of these cells in urine would not impede the diagnosis. Additionally, expression of UHRF1 was not detected in adjacent normal bladder tissues by immunohistochemistry ( Fig. 6A and 6B ). Thus, contamination of these stromal cells also would not disturb the diagnosis, either. Therefore, an immunohistochemistry or Enzyme-Linked ImmunoSorbent Assay (ELISA)-based UHRF1 detection in urine sediment can be a sensitive and cancer-specific diagnostic method, and may greatly improve the current diagnosis based on cytology. 
Conclusion
Although UHRF1 expression in muscle invasive cancer was greater than in non-invasive (pTa) or superficially invasive (pT1) cancers, UHRF1 could still be detected by immunohistochemistry in the early stage bladder cancers. In addition, overexpression of UHRF1 was associated with increased risk of progression after TURBT. Therefore, our result indicates that detection of UHRF1 may be a useful marker for early stage bladder cancers, and also for estimation of risk after TURBT, although it should be tested in larger series to determine if it can improve current strategies for diagnosis and prognosis of bladder cancer.
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